Financial Statements
Acer Therapeutics Inc. (ACER)
$0.6601
-0.14 (-17.95%)
Year | XLSX 2022 | XLSX 2021 | XLSX 2020 | XLSX 2019 | XLSX 2018 |
---|---|---|---|---|---|
Operating Cash Flow | -30,251.90 | -134.91 | -17,027.42 | -29,506.95 | -16,587.80 |
Net Income | -26,237.31 | -15,373.99 | -22,885.45 | -29,417.97 | -21,280.89 |
Depreciation & Amortization | 66.03 | 70.91 | 70.81 | 58.28 | 27.74 |
Deferred income taxes | - | - | 122.58 | - | - |
Stock-based compensation | 1,840.50 | 2,287.01 | 2,224.15 | 2,612.86 | 1,318.15 |
Change in working capital | -7,400.74 | 13,450.07 | 3,081.26 | -2,817.70 | 3,347.19 |
Other non-cash items | 1,479.63 | -568.91 | 359.23 | 57.58 | - |
Investing Cash Flow | -171.17 | -54.94 | -10.90 | -178.97 | -95.63 |
Investments in PPE | -171.17 | -54.94 | -10.90 | -178.97 | -95.63 |
Financing Cash Flow | 20,041.52 | 7,139.05 | 10,722.25 | 92.27 | 42,710.36 |
Debt repayment | -724.93 | - | - | - | - |
Common Stock Issuance | 8,909.72 | 3,139.05 | 10,159.77 | - | 42,622.70 |
Other Financing Activites | 11,856.74 | 4,000 | 562.48 | 92.27 | 87.66 |
Accounts receivables | 5,000 | -5,000 | - | - | - |
Accounts payables | 2,407.55 | -266.38 | 1,111.02 | -472.74 | 937.96 |
Inventory | - | -1,770.60 | - | - | - |
Other working capital | -14,808.29 | 20,487.05 | 1,970.24 | -2,344.96 | 2,409.24 |
Cash at beginning of period | 12,710.76 | 5,761.57 | 12,077.64 | 41,671.28 | 15,644.35 |
Cash at end of period | 2,329.22 | 12,710.76 | 5,761.57 | 12,077.64 | 41,671.28 |
Capital Expenditure | -171.17 | -54.94 | -10.90 | -178.97 | -95.63 |
Net cash flow / Change in cash | -10,381.54 | 6,949.19 | -6,316.07 | -29,593.64 | 26,026.93 |
Free Cash Flow | -30,423.07 | -189.85 | -17,038.32 | -29,685.92 | -16,683.43 |
Acer Therapeutics Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Acer Therapeutics Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.